Literature DB >> 3539178

Cyclosporin A: tissue levels following topical and systemic administration to rabbits.

T A Bell, A G Hunnisett.   

Abstract

Plasma and aqueous levels of cyclosporin A (CsA) were determined following topical administration of CsA 1% to healthy rabbit eyes and compared with levels obtained when administered to rabbit eyes which had received corneal grafts 7-10 days previously. In addition plasma levels were determined following intramuscular administration of 50 mg CsA and the results compared with those obtained following topical administration. Topical administration to healthy rabbit eyes five times a day for three days resulted in plasma levels of CsA which were similar to those obtained over three days following an intramuscular administration of 50 mg CsA. The plasma levels in both were significantly higher than those obtained following topical administration to rabbit eyes which had received corneal grafts 7-10 days previously. Aqueous levels of CsA were lower than plasma levels, and there was no significant difference between levels obtained when CsA was administered topically to healthy eyes, to eyes which had received corneal grafts, or to the fellow eye.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3539178      PMCID: PMC1040841          DOI: 10.1136/bjo.70.11.852

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  9 in total

1.  Inhibition of the allograft reaction in corneal transplantation by cyclosporin A: an experimental study with rabbits.

Authors:  B Foets; P Vanderveeren; L Missotten
Journal:  Bull Soc Belge Ophtalmol       Date:  1983

Review 2.  Cyclosporin A.

Authors:  P J Morris
Journal:  Transplantation       Date:  1981-11       Impact factor: 4.939

3.  Some experimental and clinical studies of Cyclosporin A in renal transplantation.

Authors:  P J Morris
Journal:  Transplant Proc       Date:  1982-09       Impact factor: 1.066

4.  Corneal graft rejection: a new rabbit model and cyclosporin-A.

Authors:  P A Hunter; A Garner; K R Wilhelmus; N S Rice; B R Jones
Journal:  Br J Ophthalmol       Date:  1982-05       Impact factor: 4.638

5.  Immunological and pharmacological monitoring in the clinical use of cyclosporin A.

Authors:  P A Keown; C R Stiller; R A Ulan; N R Sinclair; W J Wall; G Carruthers; W Howson
Journal:  Lancet       Date:  1981-03-28       Impact factor: 79.321

6.  Suppression of corneal allograft rejection by cyclosporin A.

Authors:  J D Salisbury; B M Gebhardt
Journal:  Arch Ophthalmol       Date:  1981-09

7.  A radioimmunoassay to measure cyclosporin A in plasma and serum samples.

Authors:  P Donatsch; E Abisch; M Homberger; R Traber; M Trapp; R Voges
Journal:  J Immunoassay       Date:  1981

8.  Rabbit corneal allograft survival following topical administration of cyclosporin A.

Authors:  J S Kana; F Hoffmann; R Buchen; A Krolik; M Wiederholt
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-05       Impact factor: 4.799

9.  Effect of cyclosporin A on the survival of corneal grafts in rabbits.

Authors:  W F Shepherd; D J Coster; T C Fook; N S Rice; B R Jones
Journal:  Br J Ophthalmol       Date:  1980-03       Impact factor: 4.638

  9 in total
  9 in total

1.  Topical treatment of severe corneal ulcers with cyclosporin A.

Authors:  M Zierhut; H J Thiel; E G Weidle; R Waetjen; U Pleyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

2.  Liposome-bound cyclosporine: clearance after intravitreal injection.

Authors:  A A Alghadyan; G A Peyman; B Khoobehi; S Milner; K R Liu
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

3.  Liposome-bound cyclosporine: aqueous and vitreous level after subconjunctival injection.

Authors:  A A Alghadyan; G A Peyman; B Khoobehi; S Milner; K R Liu
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

4.  Prevention of experimental corneal allograft rejection in rabbits using cyclosporin-collagen shields.

Authors:  K Mahlberg; R J Uusitalo; B Gebhardt; H E Kaufman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

5.  Diclofenac sodium and cyclosporin A inhibit human lens epithelial cell proliferation in culture.

Authors:  P Cortina; M J Gómez-Lechón; A Navea; J L Menezo; M C Terencio; M Diaz-Llopis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-03       Impact factor: 3.117

6.  A compartmental model for the ocular pharmacokinetics of cyclosporine in rabbits.

Authors:  C Oh; B A Saville; Y L Cheng; D S Rootman
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

7.  Penetration of 2% cyclosporin eyedrops into human aqueous humour.

Authors:  M Diaz-Llopis; J L Menezo
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

8.  Ocular penetration of cyclosporin A. III: The human eye.

Authors:  D BenEzra; G Maftzir; C de Courten; P Timonen
Journal:  Br J Ophthalmol       Date:  1990-06       Impact factor: 4.638

9.  Short-term Efficacy of Topical Immunosuppressive Agents on the Survival of Cultivated Allo-Conjunctival Equivalents.

Authors:  Young Joo Shin; Mee Kum Kim; Joo Youn Oh; Won Ryang Wee; Jin Hak Lee; Jung Hwa Ko; Hyun Ju Lee; Jae Lim Lee; Byung Moo Min; Young Suk Sohn
Journal:  Korean J Ophthalmol       Date:  2008-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.